Reduction of Night-time Blood Pressure in Pediatric Renal Transplant Recipients

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

January 31, 2020

Study Completion Date

August 31, 2020

Conditions
Hypertension Secondary to Kidney Transplant
Interventions
DRUG

New Medication: Enalapril, Isradipine, Propranolol

"Enalapril will be added in the evening at 8 pm. If the subject is already on an ACEI or there is a contraindication to starting an ACEI the subject will be started on isradipine instead. If the subject is already on an ACEI and calcium channel blocker at baseline, propranolol will then be the new medication added.~Dosing will be as follows:~ACEI: Enalapril \< 40 kg starting dose 2.5 mg titrate to 5 mg \> 40 kg starting dose 5 mg titrate to 10mg Calcium Channel Blocker: Isradipine \< 40 kg 2.5 mg \> 40 kg starting dose 2.5 mg titrate to 5 mg Beta Blocker: Propranolol \<40 kg starting dose 10 mg titrate to 20 mg \>40 kg starting dose 20 mg titrate to 40 mg"

Trial Locations (2)

11040

Cohen Children's Medical Center of NY, New Hyde Park

19104

Children's Hospital of Philadelphia, Philadelphia

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Children's Hospital of Philadelphia

OTHER

lead

Northwell Health

OTHER

NCT01007994 - Reduction of Night-time Blood Pressure in Pediatric Renal Transplant Recipients | Biotech Hunter | Biotech Hunter